Acting in the right place at the right time is the key to effective medical treatment with minimal side effects. However, ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

Valentine’s Day has come and gone, but it’s never too late to focus on your heart health. A groundbreaking new study suggests that sotagliflozin, a drug recently approved to treat type 2 diabetes and ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce heart attacks and ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...